NICE has recommended Isatuximab for people with difficult-to-treat multiple myeloma (MM).
Isatuximab, administered as an intravenous infusion, plus pomalidomide and dexamethasone is recommended for use within the Cancer Drugs Fund as an option for treating relapsed and refractory multiple myeloma in adults.
It will be offered as a treatment option to those people who have had lenalidomide and a proteasome inhibitor, and whose disease has progressed from their last treatment if they have had three previous forms of treatment.
Our independent appraisal committee has recognised more treatment options are needed for those with difficult-to-treat multiple myeloma.
Meindert Boysen, deputy chief executive and director of the Centre for Health Technology Evaluation at NICE
The treatment could not be recommended for routine use on the NHS because the cost-effectiveness estimates are uncertain as there are limitations in the clinical data.
However collecting more data from an ongoing trial, and from NHS practice, will help to address some of the uncertainties meaning it can be recommended for use within the Cancer Drugs Fund.
Around 500 people a year (5,700 new cases of MM diagnosed each year in the UK) are set to benefit from NICE’s recommendation.